UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): October 13, 2005



                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)



         Delaware                       0-16375                  94-3018487
         ---------                      --------                 ----------
(State or other jurisdiction of  (Commission File Number)     (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                                2711 Citrus Road
                        Rancho Cordova, California 95742
    (Address and telephone number of principal executive offices) (Zip Code)

                                 (916) 858-5100
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))


<PAGE>



Section 1 - Registrant's Business and Operations
------------------------------------------------

Item 1.01 Entry into a Material Definitive Agreement

     On  October  13,  2005,   ThermoGenesis   Corp.  ("TGC")  entered  into  an
International Distribution Agreement (the "Agreement") with Amersham Biosciences
AB,  a GE  Healthcare  company  headquartered  in  Sweden  ("GEHC").  Under  the
Agreement,  GEHC will become the  exclusive  worldwide  distributor  and service
provider of TGC's Auto  Xpress(TM)  System and  BioArchive(R)  System.  TGC will
receive from GEHC  non-recurring  fees for distribution and service rights,  and
technology access in consideration for rights granted under the Agreement.  GEHC
will purchase  products from TGC to distribute and service.  On an annual basis,
if certain sales projections are exceeded,  the purchase price GEHC will pay for
TGC products will be increased with respect to such excess sales.  The Agreement
has an initial  expiration  date of December 31,  2010,  but will be renewed for
additional  2 year  periods  unless  terminated  by one of the parties 12 months
prior  to the end of the  then  current  term.  TGC  agrees  to  retain  certain
employees to provide sales and  technical  support for the products for a period
of 27 months.  The  Agreement  requires GEHC to purchase  minimum  quantities of
products each year for re-sale and  distribution.  The foregoing is qualified in
its entirety by the International  Distribution Agreement. For more information,
see the Agreement attached as Exhibit 10.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

         Exhibit No.                Exhibit Description

         10                         International Distribution Agreement between
                                    ThermoGenesis Corp. and Amersham Biosciences
                                    AB dated October 13, 2005





<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                              THERMOGENESIS CORP.,
                              a Delaware Corporation


Dated:  October 18, 2005      /s/ Matthew Plavan
                              --------------------------------------------
                              Matthew Plavan,
                              Chief Financial Officer


<PAGE>


                                  EXHIBIT INDEX


         Exhibit No.                Exhibit Description

         10                         International Distribution Agreement between
                                    ThermoGenesis Corp. and Amersham Biosciences
                                    AB dated October 13, 2005
[{"type": "8-K", "sequence": "1", "filename": "for1013058k.txt", "secsgml_size_bytes": 4652}]
{"company-data": {"conformed-name": "THERMOGENESIS CORP", "cik": "0000811212", "assigned-sic": "3821", "irs-number": "943018487", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-82900", "film-number": "051143333"}, "business-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742", "phone": "9168585100"}, "mail-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742"}, "former-company": {"former-conformed-name": "INSTA COOL INC OF NORTH AMERICA", "date-changed": "19920703"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): October 13, 2005

                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)

         Delaware                       0-16375                  94-3018487
         ---------                      --------                 ----------
(State or other jurisdiction of  (Commission File Number)     (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                                2711 Citrus Road
                        Rancho Cordova, California 95742
    (Address and telephone number of principal executive offices) (Zip Code)

                                 (916) 858-5100
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section 1 - Registrant's Business and Operations
------------------------------------------------

Item 1.01 Entry into a Material Definitive Agreement

     On  October  13,  2005,   ThermoGenesis   Corp.  ("TGC")  entered  into  an
International Distribution Agreement (the "Agreement") with Amersham Biosciences
AB,  a GE  Healthcare  company  headquartered  in  Sweden  ("GEHC").  Under  the
Agreement,  GEHC will become the  exclusive  worldwide  distributor  and service
provider of TGC's Auto  Xpress(TM)  System and  BioArchive(R)  System.  TGC will
receive from GEHC  non-recurring  fees for distribution and service rights,  and
technology access in consideration for rights granted under the Agreement.  GEHC
will purchase  products from TGC to distribute and service.  On an annual basis,
if certain sales projections are exceeded,  the purchase price GEHC will pay for
TGC products will be increased with respect to such excess sales.  The Agreement
has an initial  expiration  date of December 31,  2010,  but will be renewed for
additional  2 year  periods  unless  terminated  by one of the parties 12 months
prior  to the end of the  then  current  term.  TGC  agrees  to  retain  certain
employees to provide sales and  technical  support for the products for a period
of 27 months.  The  Agreement  requires GEHC to purchase  minimum  quantities of
products each year for re-sale and  distribution.  The foregoing is qualified in
its entirety by the International  Distribution Agreement. For more information,
see the Agreement attached as Exhibit 10.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

         Exhibit No.                Exhibit Description

         10                         International Distribution Agreement between
                                    ThermoGenesis Corp. and Amersham Biosciences
                                    AB dated October 13, 2005
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                              THERMOGENESIS CORP.,
                              a Delaware Corporation

Dated:  October 18, 2005      /s/ Matthew Plavan
                              --------------------------------------------
                              Matthew Plavan,
                              Chief Financial Officer
EXHIBIT INDEX

         Exhibit No.                Exhibit Description

         10                         International Distribution Agreement between
                                    ThermoGenesis Corp. and Amersham Biosciences
                                    AB dated October 13, 2005